Upozornění: Text přílohy byl získán strojově a nemusí přesně odpovídat originálu. Zejména u strojově nečitelných smluv, kde jsme použili OCR. originál smlouvy stáhnete odsud
IMG’s contract number: ......................
SETTLEMENT AGREEMENT
(the "Agreement")
Ústav molekulární genetiky AV ČR, v. v. i.
(in English commonly referred to as the “Institute of Molecular Genetics of the Czech Academy of Sciences”)
with registered office: Vídeňská 1083, 142 20 Prague 4, Czech Republic
ID: 68378050
DIC: CZ68378050
Represented by: RNDr. Petr Dráber, DrSc., Director
registered in the register of public research institutions maintained by the Ministry of Education, Youth and Sports
(hereinafter referred to as "IMG")
and
BBD BioPhenix S.L.
with registered office: Gipuzkoa Scientific & Technological Park, Pº Mikeletegi 56, 20009 San Sebastian,
Spain
ID number: B75082669
Represented by: xxx
(hereinafter referred to as "Biobide")
collectively, the "Parties"
Preamble
1. A contract for the provision of Zebrabase (software as a service) has been concluded between IMG (as the provider) and Biobide. Based on price quote C0001_BBD_2024_03 from 29th November 2024, Biobide was supposed to pay EUR 1934 excl. VAT for Zebrabase access during the year 2024. Invoice No. 7743/0097/24 was issued and delivered to Biobide; however, it has never been paid. In accordance with the Zebrabase General Terms and Conditions, article 6 section 6.4, if the license fee is not duly and timely paid, i.e., it is not paid within its due date, the license agreement shall automatically terminate from the outset, and IMG shall be entitled to a contractual penalty of EUR 300.
2. Biobide was provided continuous access to Zebrabase in 2025 as well, while negotiations regarding a possible installment plan for the payment for services provided in 2024 as well as 2025 took place. However, since no agreement was reached, IMG suspended Zebrabase access on 6th May 2025.
3. The subject of this Agreement is the settlement of legal matters between the Parties.
4. Biobide is interested in having further access to Zebrabase, and IMG is interested in providing it, subject to resolving the outstanding debt from Biobide.
Article I.
1. The Parties agree to the following:
a. Biobide shall pay EUR 2879 excl. VAT in total, which is the sum of:
i. EUR 1934 excl. VAT for the Zebrabase access in 2024,
ii. EUR 300, as a contractual penalty, and
iii. EUR 645 excl. VAT for the Zebrabase access from 1st January 2025 till 30th April 2025.
b. IMG shall issue an invoice for the amount of EUR 2879 excl. VAT. The first payment of 50% of the total amount shall be due 14 days from the issuance date. The second payment of the remaining 50% shall be due 45 days from the issuance date. Should the invoice be paid in full and in time, IMG waives its claim for payment of interest on late payment of the aforementioned claims, as well as any claims for damages or other losses, penalties, interest on late payment and/or other sanctions. If the first payment is not made within the due date, the remaining balance shall become immediately due and payable on the day following the due date of the first payment. Additionally, IMG is entitled to 1) a contractual penalty of 0.05 % of the amount owed for each day of delay with the payment and 2) interest on the amount owed in accordance with Czech laws.
2. If the first payment (50 % of the total owed amount) is paid in full and in a timely manner, IMG agrees to conclude a new Zebrabase licence agreement with Biobide, the draft of which shall be provided to Biobide without unreasonable delay.
Article II.
1. This Agreement shall be governed by the law of the Czech Republic. The Parties exclude the application of conflict of laws rules of international law. In accordance with the provisions of Section 89a of Act No. 99/1963 Coll., the Code of Civil Procedure, as amended, the Parties agree to the local jurisdiction of the court of first instance in the place of the Provider's registered office for the settlement of disputes arising from the Agreement.
2. This Agreement is concluded on the date of signature by both Parties and becomes effective on the date when it is published in Contract Register according to Act No. 340/2015 Coll., as amended. The Contracting Parties agree that publishing in Contract Register will be ensured by IMG.
3. This Agreement shall be drawn up in two counterparts, each of which shall have the force of an original and of which one counterpart shall be given to each of the Parties. If the Agreement is signed by qualified or advanced electronic signatures, it shall be executed in one electronic copy only.
4. The Parties confirm that they have read this Agreement before signing it and that they agree to its contents without reservation. The Agreement is an expression of their true, genuine, free and serious will.
Prague, ………………………
San Sebastian, ………………..
Ústav molekulární genetiky AV ČR, v. v. i.
................................................
BBD BioPhenix S.L.U.
................................................
RNDr. Petr Dráber, DrSc.
………………………
Director
……………………….
3
image1.emf
image2.emf